Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer

Research output: Contribution to journalArticle

Abstract

Combination immunotherapy is emerging as a promising approach for the treatment of advanced prostate cancer. This research highlight discusses the combination of a PSA-directed poxviral vaccine and a monoclonal antibody blocking an important immune checkpoint molecule to treat men with metastatic castrationresistant prostate cancer. The results demonstrate feasibility and safety, as well as intriguing clinical responses to this combination therapy.

Original languageEnglish (US)
Pages (from-to)520-521
Number of pages2
JournalAsian Journal of Andrology
Volume14
Issue number4
DOIs
StatePublished - Jul 2012

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer'. Together they form a unique fingerprint.

  • Cite this